drugset / Trial / NCT00905606
Topiramate 25 mg Tablets Under Fasting Conditions
RandomizedCrossoverOpen-labelOther
Summary
The objective of this study was to compare the rate and extent of absorption of topiramate 25 mg tablets (test) versus Topamax® (reference) administered as 2 x 25 mg tablets under fasting conditions.
Timeline
- Start
- 2001-06
- Primary completion
- 2001-06
- Completion
- 2001-06
Outcome
Met primary endpoint
registry Ratio of the LS Mean (test/ref x 100) 93.91 (90% CI 85.42 to 103.25) NCT00905606 ↗
registry Ratio of the LS Mean (test/ref x 100) 98.27 (90% CI 94.63 to 102.05) NCT00905606 ↗
registry Ratio of the LS Mean (test/ref x 100) 98.19 (90% CI 94.64 to 101.87) NCT00905606 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Topiramate | Small molecule | 50 mg | — |
Indications
No indication recorded.